ADMA Biologics (ADMA) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed ADMA Biologics (ADMA) over the past year, gaining 41.2% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with +100.5% for PHVS. ADMA Biologics is the larger company by market cap ($2.28 billion vs $2.15 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | PHVS |
|---|---|---|
| Share price | $10.19 | $30.57 |
| Market cap | $2.28B | $2.15B |
| 1-day change | +0.49% | -3.52% |
| YTD return | -44.41% | +14.16% |
| 1-year return | -27.52% | +41.18% |
| 5-year return | +821.82% | +100.51% |
| P/E ratio (TTM) | 14.56 | — |
| Forward P/E | 10.80 | — |
| EPS (TTM) | $0.70 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $43.25 |
| 52-week low | $7.21 | $20.65 |
| Distance from 52-week high | -50.19% | -29.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +66.83% | +87.21% |
| Average volume | 2.63M | 731.42K |
| Shares outstanding | 223.98M | 70.20M |
| Employees | 640 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed ADMA by 68.7 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
ADMA vs PHVS FAQ
Which is bigger, ADMA Biologics or Pharvaris N.V.?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.28B compared with $2.15B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, ADMA or PHVS?
PHVS returned +41.18% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Pharvaris N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ADMA Biologics and Biotechnology: Pharmaceutical Preparations for Pharvaris N.V..